PHC Holdings Corporation (TYO:6523)
Japan · Delayed Price · Currency is JPY | Market Cap | 125.50B +6.6% |
| Revenue (ttm) | 364.40B +0.8% |
| Net Income | 492.00M -95.3% |
| EPS | 3.87 -95.3% |
| Shares Out | 126.51M |
| PE Ratio | 256.33 |
| Forward PE | 8.92 |
| Dividend | 42.00 (4.41%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 613,600 |
| Average Volume | 256,255 |
| Open | 957.00 |
| Previous Close | 952.00 |
| Day's Range | 957.00 - 995.00 |
| 52-Week Range | 856.00 - 1,189.00 |
| Beta | 0.62 |
| RSI | 41.87 |
| Earnings Date | May 13, 2026 |
About PHC Holdings
PHC Holdings Corporation, together with its subsidiaries, provides healthcare digital and precision technology solutions in Japan, Europe, North America, and internationally. The company operates in three segments: Diabetes Management; Healthcare Solutions; and Diagnostic and Life Sciences. It offers precision anatomical pathology for cancer, including tissue processors, digital pathology, and histology consumables; cell growth and preservation, such as CFC-free ultra-low temperature freezers, CO2 incubators, and live cell metabolic analyzer an... [Read more]
Financial Performance
In fiscal year 2026, PHC Holdings's revenue was 364.40 billion, an increase of 0.78% compared to the previous year's 361.59 billion. Earnings were 492.00 million, a decrease of -95.31%.
Financial StatementsNews
PHC Holdings Earnings Call Transcript: Q4 2026
FY 2025 saw record revenue and operating profit, driven by strong BGM performance and cost improvements, despite FX losses. FY 2026 guidance anticipates stable dividends, profit growth, and continued structural reforms, with upside potential if market recovery accelerates.
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics
RUNCORN, United Kingdom--(BUSINESS WIRE)-- #AI--Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Mindpeak, a leading provider of a...